Abstract
Based on the recent advances in genomic medicine, genome-wide association studies (GWASs) are now one of the main and basic technologies to detect susceptibility genes for complex disorders, including psychiatric disorders. This method also contributes the translational evidence between genomics and clinical medicine by detecting the related genes for treatment response or side effect caused by drugs, known as pharmacogenomics (PGx) .
In this article, we review the recent findings of the GWASs and PGx for mood disorders and discuss with the future direction of the “mood disorder” genetics.
